Ziccum signs agreement for Vaccine Evaluation project with major US Biomanufacturing corporation
Ziccum AB (publ) (‘Ziccum’) has signed a Material Transfer and Evaluation Agreement for a Vaccine Evaluation project with one of the most important technology-focused Biomanufacturing corporations in the US. The project is funded and will focus on evaluating the potential for new dry, thermostable forms of an advanced viral vaccine, using Ziccum’s unique formulation and drying technology LaminarPace. Ziccum has signed three agreements for funded partner studies since May 2023, and these add up to combined revenues of 10 MSEK.
The new agreement is the third major partner contract for funded Feasibility studies that Ziccum has signed in recent months. It significantly broadens the company’s strategic and biotherapeutic position. Strategically, it is the first agreement for the company with a Biomanufacturing corporation- a vital industry segment in vaccine manufacturing.
The project aims to evaluate Ziccum’s unique formulation and drying technology, LaminarPace, for treatment of an advanced viral vaccine material. The material belongs to one of the three high-potential vaccine platforms that Ziccum targets and has worked on in-house. If successful, the project will represent a significant step forward in demonstrating LaminarPace’s potential across markets and modalities.
Ziccum’s new partner company is one of the US’ largest technology-focused Biomanufacturing corporations. It has a portfolio of domestic and international partners providing advanced, end-to-end manufacturing solutions for comprehensive pandemic preparedness. The company has capabilities in vaccines, gene therapy, cell therapy, nucleic acids and more.
This third agreement for funded studies signed with a major, international corporation in recent months confirms the significant acceleration Ziccum has made in its business development and strategic and scientific progress over the last year since the appointment of new CEO Ann Gidner in 2022. In total, the three agreements for partner studies give Ziccum a combined revenue of 10 milion SEK for the initial steps agreed upon.
Ziccum Chairman Fredrik Sjövall: “This is a great step forward for us strategically, covering a new vaccine platform and an important new key market segment. We can’t wait to get the project started!”
CEO Ann Gidner: “We are honored that our technology will be evaluated by such an important partner for technological and medical advancement. As someone with extensive experience in Biomanufacturing industry right from its inception, I’m aware of the competitive advantage the future use of LaminarPace could generate for this type of partner. This Agreement reflects that innovation in vaccine formulation, and new stable and thermostable formulations, could play a fantastic role in making the world better prepared for pandemics.”